Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
A Phase I/IIA Study to Assess Safety, Tolerability and Preliminary Activity of the Combination of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Patients With Advanced Solid Malignancies (FAK-PD1)
Sponsor: Cancer Research UK
This PHASE1/PHASE2 trial investigates Carcinoma, Non-small-cell Lung and Mesothelioma and is currently ongoing. Cancer Research UK leads this study, which shows 9 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
-
Mar 2022 — Jun 2022 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Jun 2017 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer Research UK
- Merck Sharp & Dohme LLC
- NHS Greater Glasgow and Clyde
- Queen's University, Belfast
- University of Edinburgh
- University of Glasgow
- University of Leicester
- University of Southampton
- Verastem, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Belfast, United Kingdom
- • Edinburgh, United Kingdom
- • Glasgow, United Kingdom
- • Leicester, United Kingdom
- • Southampton, United Kingdom